|
To study the effects of CD25 and low dose Cyclosporin in the treatment of active Psoriasis vulgaris Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about To study the effects of CD25 and low dose Cyclosporin in the treatment of active Psoriasis vulgaris conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. To study the effects of CD25 and low dose Cyclosporin in the treatment of active Psoriasis vulgaris Clinical research trials and To study the effects of CD25 and low dose Cyclosporin in the treatment of active Psoriasis vulgaris medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as To study the effects of CD25 and low dose Cyclosporin in the treatment of active Psoriasis vulgaris. To study the effects of CD25 and low dose Cyclosporin in the treatment of active Psoriasis vulgaris Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a To study the effects of CD25 and low dose Cyclosporin in the treatment of active Psoriasis vulgaris clinical trial. Subjects often receive the most expert healthcare possible for their To study the effects of CD25 and low dose Cyclosporin in the treatment of active Psoriasis vulgaris condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > To study the effects of CD25 and low dose Cyclosporin in the treatment of active Psoriasis vulgaris  To study the effects of CD25 and low dose Cyclosporin in the treatment of active Psoriasis vulgaris
To study the effects of CD25 and low dose Cyclosporin in the treatment of active Psoriasis vulgaris
For Condition: Psoriasis
Status: Recruiting
Sponsor(s): Protein Design Labs ,
Synopsis: This study compares the efficacy and analyzes the cellular effects of anti-TAC (Daclizumab) and Cyclosporine in the treatment of psoriasis vulgaris. This is a three-armed study-Daclizumab alone, Cyclosporine alone, and the combination of both Daclizumab and Cyclosporine.
Details: The purpose is to study the safety and effectiveness of a new drug called "anti-TAC" (anti-CD25) Monoclonal Antibody used together with low dose Cyclosporine in the treatment of psoriasis. While the exact cause of psoriasis is unknown, it is believed to involve white blood cells called lymphocytes, which become activated in the skin. It is believed that these activated cells are responsible for the changes you see as the rash of psoriasis. Anti-TAC (anti-CD25) Monoclonal Antibody is designed to block the activation of these lymphocytes. Because the anti-TAC (anti-CD25) Monoclonal Antibody targets the specific cells involved in the symptoms of psoriasis, this new drug may be a better way to treat psoriasis. The second drug, Cyclosporine, is an FDA-approved drug in the treatment of psoriasis. There is evidence in the laboratory that Cyclosporine and anti-TAC, used together, will have an additive effect. An additional benefit of this study is that we are using a lower dose of cyclosporine than is usually given when it is used alone because it is being used together with anti-TAC. This should reduce the side effects usually seen with higher doses of Cyclosporine when it is used as a single drug for psoriasis. The purpose of this study is to test the safety and effectiveness of anti-TAC (Monoclonal Antibody and low dose cyclosporine in patients with active, moderate to severe psoriasis vulgaris. We also hope to gain more information on how anti-TAC works in the body
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - extensive active psoriasis vulgaris, body surface area more than 10% if accompanied by psoriatic arthritis, - negative hepatitis and HIV, - no treatment with topical medications for 2 weeks prior to the start of the study, - no treatment with systemic drugs for 1 month prior to the start of the study
Total Enrollment: 30
Location and Contact Information:
Rockefeller University *Recruiting*
New York City, New York, 10021
United States
Recruiting Pat Gilleaudeau 212-327-8333
Additional Information:
Study ID Numbers: JKR-0336;
Study Start Date: October 1997
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00050648
Other Psoriasis Studies:
1. Scalp Psoriasis Treatment with a Fiber Optic Comb
2. To study the use of Humanized CD25 in preventing the relapse of Psoriasis Vulgaris
3. A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients
4. A Pilot Study of Topical Antiflammin-2 for Psoriasis
5. Conditioning, the Placebo Effect, and Psoriasis
Related Studies:
Other Psoriasis Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
To study the effects of CD25 and low dose Cyclosporin in the treatment of active Psoriasis vulgaris
|
|
|
|
|
|
|
|
